National Center for Emerging and Zoonotic Infectious Diseases



Point Prevalence Survey of Healthcare Associated Infection (HAI) and Antimicrobial use (AU) in US nursing homes: Summary of Antimicrobial use (AU) data

Data from Centers for Disease Control and Prevention (CDC)
& the Emerging Infections Program (EIP)

July 11, 2019

Nicola Thompson, MSc, PhD

Division of Healthcare Quality Promotion, CDC

Primary objectives: CDC 2017 NH prevalence survey

- Measure number/proportion of HAIs and HAI types in nursing homes
 - Using revised McGeer criteria for residents in LTC¹
- Identify number/proportion and types of antimicrobial drugs used in nursing home residents

CDC Prevalence Survey: Definition of Antimicrobial Use

- Systemic antimicrobial(s) received by residents at the time of the survey
 - Drug name and class
 - Administration route
 - Rationale: Treatment of infection, Prophylaxis, Non-infectious
 - Therapeutic body site
 - First date and End date: Planned duration
- Systemic: Oral/Enteral, Intravenous, Intramuscular or Inhaled route of administration
 - Main exclusions : Topical, Ophthalmic, Otic, Intranasal
- Antimicrobial: List of 130 eligible agents
 - Mostly antibiotics, but also selected antifungal or antiviral agents

Prevalence of systemic antimicrobial use (AU) in nursing homes, 2017

#NH	# NH	# residents	AU prevalence 100
	residents	≥1 AU	residents
161	15,276	1,261	8.2%

Prevalence of systemic antimicrobial use (AU) in nursing homes, 2017

#NH	# NH	# residents	AU prevalence 100
	residents	≥1 AU	residents
161	15,276	1,261	8.2%

Prevalence of systemic antimicrobial use (AU) in nursing homes <u>compared</u> to U.S acute care hospitals

# NH	# NH residents	# residents <u>></u> 1 AU	AU prevalence 100 residents
161	15,276	1,261	8.2%


#	# NH	# patients ≥1	AU prevalence 100 patients
hospitals	patients	AU	
183	11,282	5,635	49.9%

Prevalence of systemic antimicrobial use (AU) in nursing homes <u>compared</u> to LTCF in European


# NH	# NH	# residents	AU prevalence 100
	residents	≥1 AU	residents
161	15,295	1,261	8.2%

Year	Size of prevalence survey	AU Prevalence per 100 residents
European CDC, 2010	700 LTCF, 25 countries, 62,000 residents	4.3%
European CDC, 2013	1,181 LTCF, 19 countries, 77,000 residents	4.4%
European CDC, 2016	1,778 LTCF, 24 countries, 102,00 residents	4.9%


Percent of antimicrobial drugs by route of administration



Percent of antimicrobial drugs by rationale for use




Top 10 antibiotic classes – overall



Thompson et al. Abstract Presented at IDWeek 2018. San Francisco, CA

Percent of antimicrobial drugs by treatment site(s)




Thompson et al. Abstract Presented at IDWeek 2018. San Francisco, CA

Urinary tract infection: a leading cause of antimicrobial use in nursing homes


Loeb. Ontario, Canada Chronic Care Facilities, 1997. Antibiotics Used

Infection type	%
1. Respiratory tract	36
2. Urinary tract	33
3. Skin/soft tissue	13

European CDC: Prevalence Survey in Longterm Care Facilities, 2013. Antimicrobials Used




>10-fold variation in NH-specific prevalence of antibiotic use for UTI




Thompson et al. Abstract Presented at Society for Healthcare Epidemiologists in America 2019. Boston, MA

>10-fold variation in NH-specific prevalence of antibiotic use for UTI



Thompson et al. Abstract Presented at Society for Healthcare Epidemiologists in America 2019. Boston, MA

Top 10 antibiotic classes for UTI



Antibiotic for UTI ≠ UTI Surveillance Event


 NHSN LTCF Component provides criteria to identify UTI Events for surveillance purposes



Healthcare-associated Infection Surveillance Protocol for Urinary Tract Infection Events for Long-term Care Facilities

Background: The urinary tract is one of the most common sites of healthcare-associated infections, accounting for up to 20% of infections reported by long-term care facilities (LTCFs). Risk factors for developing bacteriuria and UTI include age-related changes to


- Clinical guidelines are used to guide decisions on when to initiate antibiotics for suspected UTI, one example
 - Loeb Minimum Criteria for Initiation of Antibiotics
 - Undergoing an update
- They are different!
 - Because they not used for the same purpose



Self-reported data on implementation of 15 activities in 7 domains of the CDC Core Elements, 161 NH




Thompson et al. Abstract Presented at IDWeek 2018. San Francisco, CA



Thompson et al. Abstract Presented at IDWeek 2018. San Francisco, CA

Range in facility stewardship score



Factors associated with higher stewardship score

Facility-level factor*	P-value
Ownership: For-profit, not for-profit, Government	0.6623
Number certified beds: Continuous, range 12-540	0.5656
Average daily census: Continuous, range 10-495	0.7874
Infection Preventionist (IP) full time:Yes, No	0.1132
IP completed certified# training course: Yes (56), No (101)	0.0296
CMS staffing score: 1-5 points	0.3436
Number attending physicians per 100 beds: Top vs lower 3 quartiles	0.0293
CMS Overall NH Score: 1-5 points	0.5489
CMS Quality Measure Score: 1-5 points	0.0296
CMS % long-stay residents with UTI: Continuous 1-100	0.3606

^{*}Only selected factors analyzed shown in table

Thompson et al. Abstract Presented at IDWeek 2018. San Francisco, CA

[#]SHEA, APIC or State Health Department certification

Summary

- AU prevalence in US nursing homes was 8.2 per 100 NH residents
 - On a given day, 1 in 12 residents receiving an antimicrobial
 - Much lower than in US acute hospitals
 - But, double prevalence in European LTC facilities
- Most commonly given for urinary tract infection, 30% of all AU
 - UTI AU prevalence varies across NHs
 - More than 10-fold difference in NH prevalence rates
 - Remember, antibiotic given for UTI is not the same as UTI Event for surveillance
- CDC Core Elements for Antibiotic Stewardship are being adopted by nursing homes, opportunities for improvement remain

Acknowledgements:

- All 161 participating NHs
- All EIP site staff

Thank you!

CDC Project lead: Dr. Nicola Thompson ndthompson@cdc.gov

For more information, contact CDC 1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

